Ritonavir-boosted nirmatrelvir

Revision as of 20:26, 18 January 2022 by Rossdonaldson1 (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type:
  • Dosage Forms: Oral
  • Routes of Administration:
  • Common Trade Names: Paxlovid

Adult Dosing

COVID

  • 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
    • Treatment of high risk patients with mild-to-moderate disease
    • Initiate within 5 days of symptom onset

Pediatric Dosing

COVID

  • 300 mg nirmatrelvir with 100 mg ritonavir, twice daily for 5 days
    • 12 years of age and older weighing at least 40 kilograms
    • Treatment of high risk patients with mild-to-moderate disease
    • Initiate within 5 days of symptom onset

Special Populations

Pregnancy Rating

Lactation risk

Renal Dosing

  • Adult:
    • Renally dosed: if eGFR 30-60, then 150 mg/100 mg dosing
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug
    • Many drug interactions
    • E.g. Plavix, Phenytoin, Tacrolimus, Tramadol, Statins, Hydro/oxycodone/Codeine, Diazepam/Clonazepam/Alprazolam, Fentanyl, Tamsulosin

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:

Mechanism of Action

Comments

  • 89% reduction in hospitalization or death in high risk population, and 70% reduction in hospitalizations with no deaths in standard risk population.

See Also

References